Showing results (11-20 of 51) with videos related to
Sort By:
Pageof 6
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 25, 2022
Safety of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney DiseaseShahad Alsadik, Gopinath Gnanasegaran, Luohai Chen, et al.Current Oncology Reports|May 13, 2022
What Causes Desmoplastic Reaction in Small Intestinal Neuroendocrine Neoplasms?Gowri M Ratnayake, Faidon-Marios Laskaratos, Dalvinder Mandair, et al.Nutrition and Cancer|September 1, 2020
Home Total Parenteral Nutrition for Intestinal Failure in Patients with Advanced Small Intestinal Neuroendocrine NeoplasmsMan Liu, Faidon-Marios Laskaratos, Jose Bennell, et al.Current Oncology (Toronto, Ont.)|October 27, 2023
Management Strategies and Outcomes for Small Intestinal Neuroendocrine Tumours with Involvement of the Superior Mesenteric Vessels: A Systematic ReviewElizabeth Kmiotek, Sakina Lakda, Aditya Borakati, et al.Clinical Nuclear Medicine|May 11, 2023
Safety and Efficacy of 177 Lu-DOTATATE in Neuroendocrine Tumor Patients With Extensive Bone DiseaseShahad Alsadik, Gopinath Gnanasegaran, Luohai Chen, et al.Journal of Neuroendocrinology|November 18, 2022
Single centre retrospective review of outcome of 177 Lu-DOTATATE peptide receptor radionuclide therapy in the treatment of progressive metastatic neuroendocrine tumours: Survival, toxicity, and prognostic factorsShahad Alsadik, Gopinath Gnanasegaran, Luohai Chen, et al.Endocrine Oncology (Bristol, England)|May 19, 2025
Octreotide infusion pump in patients with functional neuroendocrine tumors and refractory hormonal syndromeKalyan Mansukhbhai Shekhda, Eleni Armeni, Dalvinder Mandair, et al.European Journal of Nuclear Medicine and Molecular Imaging|April 9, 2021
177Lu-DOTATATE in older patients with metastatic neuroendocrine tumours: safety, efficacy and health-related quality of lifeLuohai Chen, Shaunak Navalkissoor, Ann-Marie Quigley, et al.Journal of Neuroendocrinology|September 25, 2025
Telotristat ethyl affects tumour-fibroblast crosstalk in small intestinal neuroendocrine tumoursHarry Hodgetts, Maria Castanho Martins, Luohai Chen, et al.Scandinavian Journal of Clinical and Laboratory Investigation|December 19, 2023
Plasma or serum 5-hydroxyindoleacetic acid can be used interchangeably in patients with neuroendocrine tumoursMfon Ewang-Emukowhate, Krithika Subramaniam, Francis Lam, et al.Pageof 6